YFV infection exhibits a broad spectrum of clinical presentations. Some individuals experienced a self-limited or mild febrile illness and a significant portion progress to severe manifestation, including complication of severe hemorrhage and liver diseases.

Among those who developed several diseases 30-60% dies.

Data reported at: Reno, E., Quan, N. G., Franco-Paredes, C., Chastain, D. B., Chauhan, L., Rodriguez-Morales, A. J., & Henao-Martínez, A. F. (2020). Prevention of yellow fever in travellers: an update. The Lancet Infectious Diseases, 20(6), e129–e137. https://doi.org/10.1016/S1473-3099(20)30170-5

Yellow fever virus is estimated to cause 200,000 cases of disease and 30,000 deaths each year, with 90% occurring in Africa.

40 countries are considered endemic and at high-risk for YF outbreaks.

The vaccine from Sanofi Pauster (YF-VAX) is available, the vaccination coverage remains inadequate in endemic areas, especially during outbreaks.

There is any antiviral available to support on the treatment.